60 results about "Neutrophilic cell" patented technology

A method for classifying and counting leukocytes comprises the steps of: (1) adding to a hematological sample the following fluorescence-labeled antibodies labeled with fluorescent dyes which emit fluorescences distinguishable from each other; (a) a first fluorescence-labeled antibody (1st antibody) which bonds specifically to leukocytes, (b) a second fluorescence-labeled antibody (2nd antibody) which bonds to at least one kind of neutrophilic cells, and (c) a third fluorescence-labeled antibody (3rd antibody) which bonds to at least one kind of immature granulocytic cells, in order to stain leukocytic cells in the sample, and removing erythrocytes from the sample; (2) analyzing the resulting sample using a flow cytometer to measure at least one scattered light signal and three separate fluorescence signals; (3) defining a group of granulocytic cells on the basis of intensity of the scattered light and intensity of fluorescence from the 1st antibody; (4) defining neutrophilic cells in the defined group of granulocylic cells on the basis of the intensity of the fluorescence from the 1st antibody and intensity of fluorescence from the 2nd or 3rd antibody; (5) classifying the defined group of the neutrophilic cells into groups of neutrophilic cells different in degree of maturity on the basis of the intensity of the fluorescence from the 2nd antibody and the intensity of the fluorescence from the 3rd antibody, and counting the number of cells in each of the groups.

The present invention relates to novel LRF-1 and LRF-2 proteins which are related to the CRISP family and a protein called “Neutrophil Inhibitory Factor (NIF)” isolated from the canine hookworm (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function. In particular, isolated nucleic acid molecules are provided encoding the human LRF-1 and LRF-2 proteins. LRF-1 and LRF-2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of LRF-1 or LRF-2 activity. Also provided are diagnostic methods for detecting immune system or other LRF-1- or LRF-2-related disorders and therapeutic methods for treating such disorders.

The present subject matter contemplates small molecule, fluorescent compounds having aggregation-induced emission (AIE) characteristics. The compounds can exhibit emission in the second near-infrared window (NIR-II) (1000 nm-1700 nm). The compounds can provide imaging for deeply located diseases with ultrahigh signal background ratio. For example, neutrophils carrying the present compounds can penetrate the brain and visualize inflammation deeply located within the brain tissue through intact scalp and skull.

The invention discloses a kit for content detection of neutrophil gelatinase-associated lipocalin, wherein a reagent R1 comprises Tris, NaCl, BSA, Tween-20, PEG and NaN3; a reagent R2 comprises Tris, NaCl, BSA, Tween-20, NaN3, sucrose and NGAL antibody sensitized latex particles; a NGAL reagent reference standard sample comprises Tris, NaCl, BSA, Tween-20, EDTA, NaN3 and NGAL of different contents; the NGAL antibody sensitized latex particles comprise PS nanometer latex particles and PVN nanometer latex particles, and the particle size of the PS nanometer latex particle is larger than the particle size of the PVN nanometer latex particle. The invention has the advantages of simple reagent composition, good test sensitivity, wide linearity range, good stability, low test cost and high precision, and the kit is convenient for popularization.

ACE receptors are affected in severe acute respiratory distress syndrome related coronaviruses. ACE genes are directly related to the morbidity and mortality of those with cystic fibrosis. The thick, sticky mucus in the respiratory, and digestive systems, is seen in the inherited disease cystic fibrosis. Viral induced sticky mucus in the respiratory and digestive systems can also be appreciated as a response to viral pathogens where the cycle of mucus production in vivo induces the recruitment of more mucus production to the extent that cellular damage occurs within the lower respiratory track requiring intubation as a life saving measure. In the most severe cases mechanical intubation fails due to the fact that no control over the recruitment of mucus production was achieved at the onset. SARS pathology shows inflammatory exudation in the alveoli and interstitial tissue, with hyperplasia of fibrous tissue and fibrosis. Inherited cystic fibrosis pathology shows atelectasis, mucoid impaction, acute and chronic inflammation, bronchiectasis, cyst formation, and fibrosis widespread. A virally induced disorder in relations to ACE2 receptors can be treated successfully at the early onset with inherited cystic fibrosis disease mimicking techniques with the efforts of minimizing the activity and utilization of the ACE2 receptor. Cystic fibrosis lung infections, and opportunistic pathogens contribute to chronic airway inflammation that is characterized by neutrophil/macrophage infiltration, cytokine release and ceramide accumulation. In terms of virally induced forms off ACE2 receptor pathologies, as it related to coronavirus such as Covid 19, presumably ceramide precursors which aid in intracellular transport of the virus into the cell via inflammation and remodeling is present in alveolar tissues of the lung in patients with cystic fibrosis while the same pathology occurs in patients with virally induced forms of ACE2 pathology which to often progresses to SARS or ARDS.

Methods of generating an autologous cellular vaccine comprising monocytes or neutrophils and an antigenic polypeptide or nucleotide encoding the antigenic polypeptide are provided. The antigen-loaded cell-based vaccine compositions made using these methods are also provided. Methods of using the antigen-loaded cell-based vaccine compositions are also provided and these vaccines may be used to treat cancer. Kits for carrying out the methods described herein are also provided.

The invention discloses a cDNA sequence and cloning of L-251 protein excreted by Japanese lamprey oral gland and amino acid sequence corresponding to cDNA and expression in the engineering bacteria as well as connecting protein of CD11a and CD11b beta2 integrated agent (CR3 receptor), which inhibits neutrophil leucocyte from transmitting from endothelium cell to inflammation point.

The invention relates to a cell feature extraction method, in particular to a cerebrospinal fluid cell feature extraction method based on a gray level co-occurrence matrix. The invention aims to segment and extract textural features of plasma cells, lymphocytes and neutrophils in autoimmune encephalitis cerebrospinal fluid. The method comprises the step of extracting textural features of plasma cells, lymphocytes and neutrophils in a cerebrospinal fluid image by utilizing a gray-level co-occurrence matrix.

The invention relates to isolated bispecific affinity reagents, such as antibodies or antibody fragments that bind TNFα and a marker molecule for macrophages and/or neutrophils. The affinity reagents of the invention enable pathogenic sub-populations of TNFα to be neutralised, whilst protective sub-populations of TNFα are not affected.

The invention discloses a neutrophil-like nano drug delivery system, which has a phospholipid bilayer structure and is prepared by interactive fusion of an activated neutrophil membrane stimulated by a stimulating factor and phospholipid molecules, and the particle size of the nano drug delivery system is 100-300nm. The invention further discloses a preparation method and application of the neutrophil-like nano drug delivery system. According to the neutrophil-like nano drug delivery system with the membrane-membrane fusion structure, the advantages of the liposome and the cell carrier are fully combined, the respective defects of the liposome and the cell carrier are avoided, the liposome is used for loading drugs to overcome the defect that the cell carrier is difficult to load drugs, the active targeting ability of the liposome is endowed by the activated-state neutrophil membrane, the combination of the liposome and the cell carrier is beneficial to realizing accurate delivery of the drug to the inflammation part, can improve the treatment effect, can reduce the toxic and side effects, and has broad application prospects.

The invention relates to application of a Nocardia rubra cell wall skeleton as a neutrophil modulator. The present application provides a neutrophil modulator, which comprises a component derived from the cell wall of Nocardia rubra, and which can modulate the chemotactic function, phagocytosis function, and bactericidal function (reactive oxygen species (ROS) generation, degranulation formation) of neutrophil. The neutrophil regulator disclosed by the invention can also improve the local immune microenvironment of a chronic infection wound.

The invention relates to a blood-brain barrier penetrating drug delivery system as well as a preparation method and application thereof. The blood-brain barrier penetrating drug delivery system comprises a neutrophil exosome and a drug entrapped in the neutrophil exosome, the medicine is a medicine for treating central nervous system diseases. The invention constructs a neutrophil exosome drug-loading delivery system with good biocompatibility, and the drug-loading system has biological characteristics similar to that of neutrophil, can efficiently penetrate through a blood-brain barrier, effectively respond to inflammation, and target an inflammation site, so that the drug-loading system has a good application prospect. The compound is a drug carrier with great application prospect for treating glioma and other central nervous system diseases. The invention provides a new strategy with a transformation application prospect for non-invasive inflammatory microenvironment targeted drug delivery of glioma and other central nervous system diseases.

The invention discloses an anti-tumor composition based on a nano-silver material and application of the anti-tumor composition. The anti-tumor composition comprises a drug A and a drug B, wherein the drug A is attenuated salmonella, and the drug B is sialic acid modified nano-silver. The drug A and the drug B are combined for use and can be used for preparing medicines for treating tumors. Attenuated salmonella in the anti-tumor composition is planted in a tumor site in a targeted mode, sialic acid modified nano-silver is targeted to neutrophils, and efficient targeted delivery to the tumor site is achieved under the recruitment effect of salmonella; the nano-silver reaching the tumor site can be used for enhancing the curative effect of salmonella by directly killing tumor cells and removing neutrophils, and the biological safety of bacterial treatment is improved by removing salmonella. The anti-tumor composition can solve the key bottleneck problem of salmonella in clinical application, and efficient and safe tumor treatment based on salmonella is achieved.

The invention relates to the technical field of medicines, and provides a medicine for promoting tissue regeneration. The medicine for promoting tissue regeneration comprises PBT (Polybutylene Terephthalate) or a pharmaceutically acceptable salt of the PBT. The medicine for promoting tissue regeneration, provided by the invention, has the beneficial effects that at an injured part, PBT migrates white blood cells to the injured or infected part and promotes neutrophil to activate and migrate to the injured part in vivo, so that the healing of a matrix wound is obviously stimulated and promoted.

The invention relates to a blood treatment device configured to remove anti-neutrophil cytoplasmic antibodies (ANCAs) from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix, and wherein said matrix comprises a monomeric form of proteinase 3 (PR3). The invention further relates to an extra-corporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating a medical condition associated with ANCA.

The invention belongs to the technical field of medicines, and relates to application of a beta 3-adrenergic receptor agonist in preparation of a medicine for treating or preventing brain injury. Theresearch finds that the beta 3-adrenergic receptor agonist can increase Ly6Clow mononuclear cells and macrophages expressing alternative activation markers (CD206 and PD-L2) in the brain of a cerebralhemorrhage model mouse, and reduce neutrophil and lymphocyte which are infiltrated by brain tissues; and the beta 3-adrenergic receptor agonist promotes intramedullary hematopoiesis of the Ly6Clow mononuclear cells, promotes the Ly6Clow mononuclear cells and the macrophages to express IL-10, can effectively inhibit focal brain inflammation and edema after cerebral hemorrhage, and has important clinical application value for treating the brain injury after the cerebral hemorrhage. The invention further discloses a pharmaceutical composition. The pharmaceutical composition comprises the beta 3-adrenergic receptor agonist, and can be used as a medicine for treating the brain injury caused by the cerebral hemorrhage.

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula: